All material subject to strictly enforced copyright laws. © 2022 Managing IP is part of the Euromoney Institutional Investor PLC group.

France: EPO practice: monoclonal antibodies and sequence identity

Since the first marketing authorisation for a monoclonal antibody (Mab) in the 1980s, the patent system has never stopped adding the fuel of interest to the fire of Mabs ingenuity.

In view of the ever-increasing pace of technological progress in this highly competitive field, patent applications are often filed at the stage of Mab prototypes. Patent claims have naturally adapted to this practice in order to attempt to protect not only the Mab prototypes but also downstream developments. In this context, claims based on sequence identity are often sought after by applicants.

However, the EPO practice concerning Mab sequence identity appears rather variable, all the more so given that there is no official guideline in this area. A journey through Board of Appeal decisions and examination files nonetheless enables certain conclusions to be drawn in order for applicants to be in a better position to handle examination proceedings.

Firstly, complementarity-determining regions (CDRs) are intangible for the EPO: a claim focused on a degree of identity of CDR sequences is generally not allowed in Europe. Secondly, two main forms of sequence identity claim seem to be accepted by the EPO. The first form consists of applying the degree of identity to a region broader than the CDRs while specifying that said degree of identity does not apply to CDR sequences. This type of claim has been accepted by the Board of Appeal in the decision T 0516/11. The second form consists of associating the degree of identity with at least one functional feature, which has been encouraged by the Board of Appeal in the decision T 2101/09. This strategy can be particularly useful when the functional characteristic is a reflection of an unexpected property that justifies inventive step.

Thus, it is recommended to define the degree of identity in different ways and to provide fallback positions to combine degree of identity with functional features. It is nevertheless necessary to ensure that all the combinations contemplated have direct and unambiguous support in the original application to satisfy the requirements of Article 123(2) EPC.

marro-nicolas.jpg
boudeau-berengere.jpg

Nicolas Marro

Bérengère

Boudeau


Cabinet Beau de Loménie158, rue de l’UniversitéF - 75340 Paris Cedex 07 FranceTel: +33 1 44 18 89 00Fax: +33 1 44 18 04 23contact@bdl-ip.comwww.bdl-ip.com

More from across our site

In-house and private practice counsel discuss issues with pre-grant opposition in India, including the rise of non-speaking orders and straw man filings
The US Supreme Court rejected an appeal on American Axle, dashing hopes of a judicial fix to patent eligibility uncertainty
The Copyright Office refused to grant protection on the basis that the authorship couldn’t be distinguished from the final work produced by the program
COVID vaccines top Clarivate’s new brands list; Fed Circuit reverses Coca-Cola’s TTAB win; Skechers sues Brooks; USPTO to retire Public PAIR tool; CCB sees cricket complaint
Lawyers should pay attention to APJs’ questions and remember that PTAB proceedings aren’t jury trials, say former PTAB judges
The USPTO cancelled ‘Galavava’ and 'Surfstar Wake' and partly cancelled ‘Heika’ this month
We have published all the 2022 rankings of the leading firms for patent litigation and protection work
In-house and private practice counsel say UK judges have raised the bar for preliminary injunction requests
António Campinos will serve another five years as EPO president – perhaps he’ll calm unrest at the office in that time
LGBTQ IP lawyers say using rainbow colours and posting solidarity messages on social media must be followed by concrete action
We use cookies to provide a personalized site experience.
By continuing to use & browse the site you agree to our Privacy Policy.
I agree